Xiuhua Weng*1, Shaohong Luo*1, Shen Lin*, Lixian Zhong†, Meiyue Li*, Rao Xin*, Pinfang Huang*, Xiongwei Xu*
Oncology Research, Vol.28, No.2, pp. 117-125, 2020, DOI:10.3727/096504019X15707883083132
Abstract To evaluate the cost–utility of pembrolizumab versus chemotherapy as the first-line setting for metastatic nonsmall cell lung cancer (NSCLC) from the US health care system perspective, a Markov model was developed
to compare the lifetime cost and effectiveness of pembrolizumab versus chemotherapy for untreated metastatic NSCLC, based on the clinical data derived from phase III randomized controlled trial (KEYNOTE-
042; ClinicalTrials.gov; NCT02220894). Weibull distribution was fitted to simulate the parametric survival
functions. Drug costs were collected from official websites, and utility values were obtained from published literature. Total costs, quality-adjusted life years (QALYs), and incremental… More >
Login
Register
